Novartis Gains MRSA Product Through Acquisition of Protez Pharmaceuticals
Helen Scrutton
Abstract
Novartis gains a superbug-targeting antibiotic through this acquisition of Protez Pharmaceuticals.
Full Text: pdf html
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.